Phexxi®

About Evofem Biosciences

Evofem Biosciences is a mission-driven company focused on empowering women through innovative, non-hormonal contraceptive and sexual health products. Its key achievement is the FDA approval and commercial launch of Phexxi®, a first-in-class, on-demand contraceptive gel, complemented by the strategic acquisition of Solosec® for bacterial vaginosis. The company's strategy centers on commercial execution in the U.S., securing international partnerships, and advancing its pipeline based on its pH modulation technology to address significant unmet needs in women's healthcare.

About Organon (2)

Organon is a mission-driven global healthcare company established in 2021 as a spin-off from Merck & Co., with a dedicated focus on women's health. Its strategy is built on three core pillars: advancing a portfolio of women's health therapies, expanding access through biosimilars, and maximizing the value of a broad range of established medicines. The company has achieved immediate global scale, operating in over 140 markets, and is recognized for its strong corporate governance and commitment to addressing healthcare inequities.

Therapeutic Areas